Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial
Conclusions</div>In resected stage I NSCLC patients adjuvant 400 mg/day pazopanib but not 800 mg/day was feasible, although possibly infra-therapeutic and failed to improve relapse-free survival.</span>
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Gastroenterology | Hypertension | Lung Cancer | Non-Small Cell Lung Cancer | Oral Cancer | Skin Cancer | Smokers | Squamous Cell Carcinoma | Toxicology